GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

envafolimab   Click here for help

GtoPdb Ligand ID: 10492

Synonyms: Envida® | KN-035 | KN035
Approved drug Immunopharmacology Ligand
envafolimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co [1]. Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019.
Immunopharmacology Comments
Envafolimab (KN-035) is an anti-PD-L1 immune checkpoint inhibitor that is being investigated for anti-tumour potential. It potently induces T-cell responses and inhibits tumour growth in preclinical experiments [1].